[1]	Xia C, Dong X, Li H, et al. Cancer statistics in China and United States,2022:profiles,trends,and determinants[J]. Chin Med J (Engl), 2022, 135(5):584-590. DOI:10.1097/CM9.0000000000002108. 本文引用 [1]

[2]	Yang H, Zhang K, Liu Z, et al. Clinical analysis of conformal and intensity-modulated radiotherapy in patients with recurrent ovarian cancer[J]. Sci Rep, 2020, 10(1):17172. DOI:10.1038/s41598-020-74356-7. 本文引用 [1]

[3]	Rochet N, Kieser M, Sterzing F, et al. Phase Ⅱ study evaluating consolidation whole abdominal intensity-modulated radiotherapy (IMRT) in patients with advanced ovarian cancer stage FIGO III--the OVAR-IMRT-02 Study[J]. BMC Cancer, 2011, 11:41.DOI:10.1186/1471-2407-11-41. 本文引用 [1]

[4]	Durno K, Powell ME. The role of radiotherapy in ovarian cancer[J]. Int J Gynecol Cancer, 2022, 32(3):366-371. DOI:10.1136/ijgc-2021-002462. 本文引用 [1]

[5]	Henke LE, Stanley JA, Robinson C, et al. Phase Ⅰ trial of stereotactic MRI-guided online adaptive radiation therapy(SMART) for the treatment of oligometastatic ovarian cancer[J]. Int J Radiat Oncol Biol Phys, 2022, 112(2):379-389. DOI:10.1016/j.ijrobp.2021.08.033. 本文引用 [1]

[6]	Dang YZ, Li X, Ma YX, et al. 18F-FDG-PET/CT-guided intensity-modulated radiotherapy for 42 FIGO III/IV ovarian cancer:A retrospective study[J]. Oncol Lett, 2019, 17(1):149-158. DOI:10.3892/ol.2018.9601. 本文引用 [1]

[7]	Li Y, Zhao S, Zhang F, et al. Molecular imaging-monitored radiofrequency hyperthermia-enhance intratumoral herpes simplex virus-thymidine kinase gene therapy for rat orthotopic ovarian cancer[J]. Int J Hyperthermia, 2020, 37(1):101-109. DOI:10.1080/02656736.2020.1711973. 本文引用 [1]

[8]	Onal C, Gultekin M, Oymak E, et al. Stereotactic radiotherapy in patients with oligometastatic or oligoprogressive gynecological malignancies: a multi-institutional analysis[J]. Int J Gynecol Cancer, 2020, 30(6):865-872. DOI:10.1136/ijgc-2019-001115. 本文引用 [1]

[9]

Macchia G, Lazzari R, Colombo N, et al. A large,multicenter,retrospective study on efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic ovarian cancer (MITO RT1 Study):a collaboration of MITO,AIRO GYN,and MaNGO groups[J]. Oncologist, 2020, 25(2):e311-e320. DOI:10.1634/theoncologist.2019-0309. 本文引用 [2]

[10]	Shenker R, Stephens SJ, Davidson B, et al. Role of stereotactic body radiotherapy in gynecologic radiation oncology[J]. Int J Gynecol Cancer, 2022, 32(3):372-379. DOI:10.1136/ijgc-2021-002466. 本文引用 [1]

[11]	Mohan R. A review of proton therapy - current status and future directions[J]. Precis Radiat Oncol, 2022, 6(2):164-176. DOI:10.1002/pro6.1149. 本文引用 [1]

[12]	Taunk N. The role of proton therapy in gynecological radiation oncology[J]. Int J Gynecol Cancer, 2022, 32(3):414-420. DOI:10.1136/ijgc-2021-002459. 本文引用 [1]

[13]	Kino T, Ando N, Ogawara Y, et al. Proton beam therapy for recurrent ovarian carcinoma:A case report[J]. J Obstet Gynaecol Res, 2019, 45(9):1952-1956. DOI:10.1111/jog.14036. 本文引用 [1]

[14]	Endo Y, Takagawa Y, Yoshimoto Y, et al. Proton beam therapy achieves excellent local control for recurrent epithelial ovarian cancer:a single-center retrospective study[J]. J Ovarian Res, 2025, 18(1):110. DOI:10.1186/s13048-025-01695-2. 本文引用 [1]

[15]	Barcellini A, Murata K, Fontana G, et al. The first real-world study on the role of carbon ion radiotherapy for oligo-metastatic,persistent,or recurrent (MPR) ovarian/fallopian tube cancer[J]. Clin Transl Radiat Oncol, 2024, 47:100781. DOI:10.1016/j.ctro.2024.100781. 本文引用 [1]

[16]	卢淮武, 霍楚莹, 黄纯娴, 等. 《2025 NCCN卵巢癌包括输卵管癌及原发性腹膜癌临床实践指南(第1版)》解读[J]. 中国实用妇科与产科杂志, 2025, 41(4):436-444.DOI:10.19538/j.fk2025040113. 本文引用 [1]

[17]	Ogasawara A, Sato S, Hasegawa K. Current and future strategies for treatment of ovarian clear cell carcinoma[J]. J Obstet Gynaecol Res, 2020, 46(9):1678-1689. DOI:10.1111/jog.14350. 本文引用 [1]

[18]	Brown AP, Jhingran A, Klopp AH, et al. Involved-field radiation therapy for locoregionally recurrent ovarian cancer[J]. Gynecol Oncol, 2013, 130(2):300-305. DOI:10.1016/j.ygyno.2013.04.469. 本文引用 [1]

[19]	Stevens MJ, West S, Gard G, et al. Utility of adjuvant whole abdominal radiation therapy in ovarian clear cell cancer (OCCC):a pragmatic cohort study of women with classic immuno-phenotypic signature[J]. Radiat Oncol, 2021, 16(1):29. DOI: 10.1186/s13014-021-01750-4. 本文引用 [1]

[20]	Cuccia F, Pastorello E, Vitale C, et al. The use of SBRT in the management of oligometastatic gynecological cancer:report of promising results in terms of tolerability and clinical outcomes[J]. J Cancer Res Clin Oncol, 2021, 147(12):3613-3618. DOI:10.1007/s00432-021-03802-4. 本文引用 [1]

[21]

Guckenberger M, Lievens Y, Bouma AB, et al. Characterisation and classification of oligometastatic disease:a European Society for Radiotherapy and Oncology and European Organization for Research and Treatment of Cancer consensus recommendation[J]. Lancet Oncol, 2020, 21(1):e18-e28. DOI:10.1016/S1470-2045(19)30718-1. 本文引用 [1]

[22]	Shen J, Tao Y, He L, et al. Clinical application of radiotherapy in patients with oligometastatic ovarian cancer:a sharp tool to prolong the interval of systemic treatment[J]. Discov Oncol, 2022, 13(1):82. DOI:10.1007/s12672-022-00540-y. 本文引用 [1]

[23]

Macchia G, Pezzulla D, Campitelli M, et al. Treatment of oligometastatic parenchymal lesions in ovarian cancer with stereotactic ablative radiation therapy:a multicenter prospective phase 2 trial (MITO RT3/RAD)[J]. Int J Radiat Oncol Biol Phys, 2025, 123(1):228-237. DOI:10.1016/j.ijrobp.2025.03.032. 本文引用 [1]

[24]	Macchia G, Campitelli M, Pezzulla D, et al. Stereotactic ablative radiation therapy for oligometastatic ovarian cancer lymph node disease:The MITO-RT3/RAD phase Ⅱ trial[J]. Int J Radiat Oncol Biol Phys, 2025, 121(3):693-702. DOI:10.1016/j.ijrobp.2024.09.036. 本文引用 [1]

[25]	Macchia G, Cilla S, Pezzulla D, et al. Efficacy of stereotactic body radiotherapy and response prediction using artificial intelligence in oligometastatic gynaecologic cancer[J]. Gynecol Oncol, 2024, 184:16-23. DOI:10.1016/j.ygyno.2024.01.023. 本文引用 [1]

[26]	Huck C, Kountouri M, Yarza R, et al. SBRT in recurrent oligometastatic ovarian cancer:An EORTC Y-ECI GCG systematic review[J]. Clin Transl Radiat Oncol, 2025, 53:100981.DOI:10.1016/j.ctro.2025.100981. 本文引用 [1]

[27]	Meattini I, Aznar MC, Boldrini L, et al. Repositioning Radiation Oncology at the centre of integrated oncology care:A manifesto of the European Society for Radiotherapy and Oncology (ESTRO)[J]. Radiother Oncol, 2025, 210:111035. DOI:10.1016/j.radonc.2025.111035. 本文引用 [1]

[28]	Jiang G, Balboni T, Taylor A, et al. Palliative radiation therapy for recurrent ovarian cancer:efficacy and predictors of clinical response[J]. Int J Gynecol Cancer, 2018, 28(1):43-50.DOI:10.1097/IGC.0000000000001139. 本文引用 [1]

[29]	Lee L, Matulonis U. Immunotherapy and radiation combinatorial trials in gynecologic cancer:A potential synergy?[J]. Gynecol Oncol, 2019, 154(1):236-245. DOI:10.1016/j.ygyno.2019.03.255. 本文引用 [1]

[30]	Zamarin D, Burger RA, Sill MW, et al. Randomized phase Ⅱ trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer:an NRG oncology study[J]. J Clin Oncol, 2020, 38(16):1814-1823. DOI:10.1200/JCO.19.02059. 本文引用 [1]

[31]	Gupta A, Probst HC, Vuong V, et al. Radiotherapy promotes tumor-specific effector CD8+ T cells via dendritic cell activation[J]. J Immunol, 2012, 189(2):558-566. DOI:10.4049/jimmunol.1200563. 本文引用 [1]

[32]	Ladbury C, Germino E, Novak J, et al. Combination radiation and immunotherapy in gynecologic malignancies-a comprehensive review[J]. Transl Cancer Res, 2021, 10(5):2609-2619. DOI:10.21037/tcr-20-3019. 本文引用 [1]

[33]	Qin Y, Huang S, Tang J, et al. Case report:Interstitial implantation radiotherapy combined with immunotherapy and GM-CSF in oligometastatic platinum-resistant ovarian cancer[J]. Front Immunol, 2024, 14:1329951. DOI:10.3389/fimmu.2023.1329951. 本文引用 [1]

[34]	Herrera FG, Irving M, Kandalaft L E, et al. Rational combinations of immunotherapy with radiotherapy in ovarian cancer[J]. Lancet Oncol, 2019, 20(8):e417-e433. DOI:10.1016/S1470-2045(19)30401-2. 本文引用 [1]

[35]

Tsuchino Y, Chiyoda T, Jisaka M, et al. Case report of two long term ovarian cancer survivors with brain metastases following multimodal treatment including chemotherapy,radiotherapy and maintenance olaparib:An institutional case series and literature review[J]. Gynecol Oncol Rep, 2024, 54:101444. DOI:10.1016/j.gore.2024.101444. 本文引用 [1]

[36]

Reiss KA, Herman JM, Armstrong D, et al. A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers[J]. Gynecol Oncol, 2017, 144(3):486-490.DOI:10.1016/j.ygyno.2017.01.016. 本文引用 [1]

[37]	Durante S, Cuccia F, Rigo M, et al. Stereotactic radiotherapy for managing ovarian cancer oligoprogression under poly (ADP-ribose) polymerase inhibitors (PARPi)[J]. Int J Gynecol Cancer, 2024, 34(8):1232-1239. DOI:10.1136/ijgc-2024-005361. 本文引用 [1]

[38]

Macchia G, Pezzulla D, Campitelli M, et al. Stereotactic body radiation therapy for oligoprogressive ovarian cancer patients treated during poly(ADP-ribose)-polymerase inhibitor maintenance:efficacy and adverse events from the epimetheo retrospective study[J]. Int J Radiat Oncol Biol Phys, 2025, 121(2):465-474. DOI:10.1016/j.ijrobp.2024.09.010. 本文引用 [1]

[39]	Jin ZH, Tsuji AB, Degardin M, et al. Radiotheranostic agent 64Cu-cyclam-RAFT-c(-RGDfK-)4 for management of peritoneal metastasis in ovarian cancer[J]. Clin Cancer Res, 2020, 26(23):6230-6241. DOI:10.1158/1078-0432.CCR-20-1205. 本文引用 [1]

[40]	Ma Q, Kai J, Liu Y, et al. Targeting Ku86 enhances X-ray-induced radiotherapy sensitivity in serous ovarian cancer cells[J]. Int J Biochem Cell Biol, 2020, 121:105705. DOI:10.1016/j.biocel.2020.105705. 本文引用 [1]

[41]	狄文, 胡逸凡. 妇科肿瘤规范化诊疗中的个体化:从共识到实践的再思考[J]. 中国实用妇科与产科杂志, 2026, 42(01):10-13.DOI:10.19538/j.fk2026010103. 本文引用 [1]

[42]	狄文, 张楠. 卵巢恶性肿瘤诊疗观念的思考与挑战[J]. 中国实用妇科与产科杂志, 2024, 40(11):1057-1060.DOI:10.19538/j.fk2024110101. 本文引用 [1]